Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada.
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab an interleukin-17A inhibitor, was significantly superior to Enbrel in moderate-to-severe plaque psoriasis.
Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France.
The U.S. FDA accepted a supplemental New Drug Application for Jardiance based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial.
Provepharm, a French company specialized in the development of pharmaceutical applications announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA
The U.S. FDA has approved Humalog® 200 units/mL KwikPen, a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin.
Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada